Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
about
Drug delivery to the posterior segment of the eye for pharmacologic therapy.Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.Optimal management of cytomegalovirus retinitis in patients with AIDS.Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study.Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosidesDrug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovirAntiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses.Diagnosis & management of cytomegalovirus infections in the GI tract.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.Cytomegalovirus infection and the gastrointestinal tract.Design, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3-Triazole Nucleosides.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Cytomegalovirus protease targeted prodrug development.Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?Phosphonylated Acyclic Guanosine Analogues with the 1,2,3-Triazole Linker.The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.Oral valganciclovir for colonic dilatation in ulcerative colitis associated with human cytomegalovirus infection.Prevention of cytomegalovirus reactivaction after allogenic hematopoietic stem cell transplantation with valganciclovir: single center experience.Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir.Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant RecipientsCytomegalovirus infection in immunocompetent adults: Is observation still the best strategy?
P2860
Q30478379-54DB211B-F0A4-43B6-ACFA-2CE26FE691EBQ33410582-7128CB6B-082C-462C-8BBB-A65BD31B9C66Q33715300-B5DA5EA4-90DA-43F8-9C75-A506693115CCQ33819834-72919B8B-F645-469E-B9C2-53EBED38D067Q35692301-3D3ECDDB-EF15-4A30-9083-8C248E396F9AQ35820411-741BE5E5-7692-4483-ABB2-35C517849B77Q36433206-63FBF623-F9A8-453E-9F8A-C349546B708CQ36668891-D3280268-94B9-4FB9-B5AD-B01F433EACDBQ36948496-B4BB4847-3118-408D-8A85-244CB38DBA4EQ37247594-88F79538-2B4C-496C-A9B2-AF0142F9DA96Q37252268-1FFFB52D-3654-4438-8D11-BC85ADEB1B5BQ37346001-05AFC88B-4590-45C3-ADAC-583E1CC11BC9Q37409907-95A9C550-C7F7-4D83-83BF-C02BFA284315Q37627442-E88E82A0-5F0D-4DCA-B9F6-F4EE23035356Q37949634-33DC32EE-BF61-405C-AFAA-68DBCCE7DC08Q37951633-97750840-6F63-4431-B696-6BFFCADD4F3AQ38010341-2272EE86-728E-4748-9F08-C8F8B4EF3C37Q38695987-14181458-1B04-4FA4-8DEA-0E7B49CE9CCCQ38779846-4F14BF7C-E459-421D-8094-F9C25DA07670Q39588131-2CBDE29B-3418-4483-847E-D75760C092BAQ40922185-6A25CADF-A8BB-4BD1-873A-DF29BECF4C02Q41186604-F99E581B-A7B4-4E2E-A419-3FB2B950B0ACQ43061425-2D4BBA7F-EA92-425D-8575-249A702A1891Q43284326-71F38CFD-930E-4919-802F-D0A1D3225119Q46699458-CED1B18D-6B5C-4B75-ADD0-BBAAA12E2B96Q46987210-D34658FA-1BFC-4E6F-8A32-C5AD4F26566AQ47130159-09C1F275-444B-476F-AE2C-C01FE9050CB6Q49053202-FBBBB179-C887-46DB-BC51-60714A52AC01Q57750563-B36EC21C-DA24-453D-8B43-6059A83C460BQ58697763-6E54E227-49F1-451A-8998-EEDE346DA2C5
P2860
Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Valganciclovir: a review of it ...... in immunocompromised patients.
@ast
Valganciclovir: a review of it ...... in immunocompromised patients.
@en
type
label
Valganciclovir: a review of it ...... in immunocompromised patients.
@ast
Valganciclovir: a review of it ...... in immunocompromised patients.
@en
prefLabel
Valganciclovir: a review of it ...... in immunocompromised patients.
@ast
Valganciclovir: a review of it ...... in immunocompromised patients.
@en
P1433
P1476
Valganciclovir: a review of it ...... in immunocompromised patients.
@en
P2093
Keri Wellington
Risto S Cvetković
P304
P356
10.2165/00003495-200565060-00012
P577
2005-01-01T00:00:00Z
P6179
1011584011